Table 2 Oncologic characteristics and chemotherapy drugs used
From: Emerging markers of cachexia predict survival in cancer patients
Cancer type, n (%) | Surgery, n 30 (21) | Radiotherapy, n 25 (17) | Chemotherapy, n 129 (92) |
|---|---|---|---|
Gastrointestinal cancer 27 (20%) | 11 (37) | 4 (16) | 26 (21) |
Lung and pleura cancer 25 (18%) | 3 (10) | 1 (4) | 25 (19) |
Pancreas cancer 3 (2%) | 1 (3) | - | 2 (1) |
Breast cancer 20 (14%) | 9 (30) | 9 (36) | 18 (14) |
Multiple Myeloma 13 (9%) | - | 5 (20) | 12 (9) |
Lymphomas 28 (20%) | - | 4 (16) | 25 (19) |
Head and Neck cancer 16 (11%) | 1 (3) | 2 (8) | 15 (12) |
Gynecologic cancer 8 (6%) | 5 (17) | - | 7 (5) |
Cancer Stage | Patients, n (%) | Death, n (%) | Survival, n (%) |
III* | 35 (25) | 4 (5 | 31 (68%) |
III**- IV* | 105 (75) | 90 (95%) | 15 (32%) |
Chemotherapy drugs | |||
Platinum | 59 (42) | 48 (81%) | 11 (9%) |
Anthracyclines | 55 (39) | 33 (60%) | 22 (40%) |
Taxanes | 16 (12) | 6 (37%) | 10 (63%) |
Anti-metabolites | 75 (53) | 57 (76%) | 18 (24%) |
Alkylating Agents | 18 (13) | 9 (50%) | 9 (50%) |
Vinca Alkaloids | 16 (11) | 7 (43%) | 9 (57%) |
Monoclonal Antibodies | 24 (17) | 13 (54%) | 11 (46%) |
Hormone therapy | 12 (9) | 6 (50%) | 6 (50%) |